IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by D.B. Root & Company LLC

D.B. Root & Company LLC reduced its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 2.3% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 981 shares of the company’s stock after selling 23 shares during the period. D.B. Root & Company LLC’s holdings in IDEXX Laboratories were worth $480,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Lindbrook Capital LLC lifted its stake in shares of IDEXX Laboratories by 73.3% during the first quarter. Lindbrook Capital LLC now owns 52 shares of the company’s stock worth $25,000 after buying an additional 22 shares during the period. TCI Wealth Advisors Inc. lifted its position in IDEXX Laboratories by 120.8% during the first quarter. TCI Wealth Advisors Inc. now owns 53 shares of the company’s stock valued at $26,000 after purchasing an additional 29 shares during the period. Institutional & Family Asset Management LLC lifted its position in IDEXX Laboratories by 150.0% during the fourth quarter. Institutional & Family Asset Management LLC now owns 55 shares of the company’s stock valued at $27,000 after purchasing an additional 33 shares during the period. Catalyst Capital Advisors LLC acquired a new position in IDEXX Laboratories during the fourth quarter valued at $30,000. Finally, CVA Family Office LLC acquired a new position in IDEXX Laboratories during the first quarter valued at $32,000. Institutional investors and hedge funds own 85.06% of the company’s stock.

A number of research analysts recently issued reports on the stock. Zacks Investment Research downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating and set a $519.00 target price for the company. in a research report on Tuesday, April 6th. Barclays boosted their target price on shares of IDEXX Laboratories from $600.00 to $616.00 and gave the company an “overweight” rating in a research report on Wednesday, May 5th. Finally, JPMorgan Chase & Co. assumed coverage on shares of IDEXX Laboratories in a research report on Friday, January 29th. They set an “overweight” rating and a $570.00 target price for the company. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $482.00.

Shares of IDEXX Laboratories stock opened at $530.07 on Friday. The firm has a 50-day simple moving average of $520.22 and a two-hundred day simple moving average of $494.44. The company has a market cap of $45.20 billion, a P/E ratio of 92.35, a price-to-earnings-growth ratio of 4.55 and a beta of 0.88. IDEXX Laboratories, Inc. has a fifty-two week low of $288.50 and a fifty-two week high of $573.99. The company has a debt-to-equity ratio of 1.93, a quick ratio of 1.24 and a current ratio of 1.65.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Tuesday, May 4th. The company reported $2.35 earnings per share for the quarter, topping analysts’ consensus estimates of $1.72 by $0.63. The business had revenue of $777.71 million during the quarter, compared to the consensus estimate of $738.43 million. IDEXX Laboratories had a net margin of 19.20% and a return on equity of 198.91%. The company’s revenue was up 24.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.29 earnings per share. Equities research analysts forecast that IDEXX Laboratories, Inc. will post 6.13 EPS for the current year.

In other news, CEO Jonathan Jay Mazelsky sold 13,868 shares of the business’s stock in a transaction dated Wednesday, February 17th. The shares were sold at an average price of $537.21, for a total transaction of $7,450,028.28. Following the completion of the sale, the chief executive officer now owns 68,090 shares of the company’s stock, valued at $36,578,628.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Rebecca M. Henderson sold 3,046 shares of the business’s stock in a transaction dated Tuesday, February 23rd. The stock was sold at an average price of $513.41, for a total transaction of $1,563,846.86. Following the sale, the director now directly owns 17,742 shares of the company’s stock, valued at approximately $9,108,920.22. The disclosure for this sale can be found here. In the last quarter, insiders sold 19,733 shares of company stock valued at $10,551,668. Insiders own 2.53% of the company’s stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.

Featured Article: What is the QQQ ETF?

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.